Investment analysts at MKM Partners reduced their earnings per share (EPS) estimates on shares of Pfizer (NYSE:PFE) in a note issued to investors on Thursday, Analyst Ratings Network reports. The firm currently has a “neutral” rating and a $29.00 price target on the company’s shares. MKM Partners’ price target points to a potential downside of 7.14% from the company’s current price. Pfizer Inc. (NYSE:PFE)shares after opening at $3.41 on last trade day and at the end of the day closed at $31.42. Company price to sales ratio in past twelve months was calculated as 4.15 and price to cash ratio as 6.61. Pfizer Inc. (NYSE:PFE) showed a negative weekly performance of -2.99%.
Merck & Co. (NYSE:MRK) had its price target increased by Leerink Swann from $49.00 to $57.00 in a research report sent to investors on Thursday morning, Analyst RN reports. Merck & Co., Inc. (NYSE:MRK) shares advanced 1.01% in last trading session and ended the day on $56.26. MRK return on equity ratio is recorded as 12.10% and its return on assets is 5.60%. Merck & Co., Inc. (NYSE:MRK) yearly performance is 32.13%.
Five Prime Therapeutics’ latest deal — a potential $350 million-plus cancer-fighting collaboration with drug powerhouse Bristol-Myers Squibb Co (NYSE:BMY) — sent shares of the South San Francisco biotech company up Monday nearly 23 percent. Bristol-Myers Squibb (NYSE: BMY) will take a 4.9 percent stake in Five Prime (NASDAQ: FPRX) and make an upfront payment of $20 million in exchange for exclusive worldwide rights to develop and sell drugs directed toward specific protein targets identified by Five Prime. Bristol-Myers Squibb Co (NYSE:BMY) shares moved up1.33% in last trading session and was closed at $54.72, while trading in range of $54.18 – $54.90. Bristol-Myers Squibb Co (NYSE:BMY) year to date (YTD) performance is 2.95%.
Like McDonald’s (MCD), Johnson & Johnson (NYSE:JNJ) is a household name that offers steady profit growth, making it a classic dividend play for income investors. The fellow S&P 500 Dividend Aristocrat’s wide range of consumer brands include Aveeno, Band-Aid, Tylenol and Splenda. But medical devices, diagnostic equipment and pharmaceuticals account for the bulk of its revenue. Johnson & Johnson (NYSE:JNJ) weekly performance is 0.51%. On last trading day company shares ended up $93.93. Johnson & Johnson (NYSE:JNJ) distance from 50-day simple moving average (SMA50) is 2.57%. Analysts mean target price for the company is $100.90.